Pauline Springorum

Amsterdam Netherlands

Contact Me Today

Pauline is an associate in our Patents & Innovation team. She advises clients on various matters related to intellectual property and has a keen interest in life sciences. Pauline primarily focuses on litigation and has gained international experience by pleading before the Unified Patent Court (UPC).

She supports national and international clients in complex patent disputes across a range of technical fields, helping them navigate the challenges of enforcement and defense. Since 2024, Pauline has been a UPC representative, representing multiple clients before the UPC courts and gaining valuable insight into the specific challenges linked to this unprecedented system. With a practical mindset and a strategic approach, she is committed to securing the best possible outcomes for her clients.

CV

Since 2022 Associate, Taylor Wessing

2021-2022 Paralegal, Visser Schaap Kreijger

Career

Since 2022 Associate, Taylor Wessing

2021-2022 Paralegal, Visser Schaap Kreijger

Education

2021 LLM, Civil Law, Leiden University

2020 Exchange, Queen Mary University of London

2018 LLB, Dutch Law, Leiden University

Publications

Non-Fungible Tokens en auteursrecht (Bedrijfsjuridische berichten) (Bb 2021/98)
Ars Aequi Wettenbundel Intellectuele Eigendom 2022 (editor)
Ars Aequi Wettenbundel Intellectuele Eigendom 2024 (editor)

Additional languages

Pauline's news & insights

View Pauline's insights

Click here to find out more

Patents & innovation

Preliminary injunctions in the Netherlands

23 September 2025

by multiple authors

Synapse - AI in Life Sciences

UPC litigation in life sciences: seven early takeaways for the pharma, biotech and medical devices sectors

The Unified Patent Court (UPC) has become a crucial forum for life sciences patent litigation. Early rulings show strict claim interpretation, careful review of European Patent Office oppositions, and limits on the Bolar exemption. The UPC has clarified infringement tests for second medical use claims and considers patient interests in injunctions. These developments emphasise precise patent strategy, regulatory alignment, and proactive risk management for pharma, biotech, and medical device sectors.

17 June 2025

by Yolandi Coetzee and Pauline Springorum

1 of 5 Insights

Click here to find out more